Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway

Abstract

Immune checkpoint inhibitors such as monoclonal antibodies (mAbs) are amongst the most important breakthroughs in cancer therapeutics. However, high cost and short acting time limits its affordability and clinical application. Therefore, an economical and durable alternative is urgently needed. Previously, we identified an IL-17RB targeting mAb which intercepts IL-17B/IL-17RB signal transduction and suppresses tumorigenesis in many types of cancer. We reason that active immunity against the antigenic epitope of IL-17RB can reproduce the anti-cancer effect of mAbs with better sustainability. Here, we present a cancer vaccine composed of multiple synthesized epitope peptides chemically conjugated onto CRM197, a highly immunogenic carrier protein. Combining mass spectrometry with immunoassay, we standardized hapten density determination and optimized vaccine design. Furthermore, orthotopically transplanted syngeneic mouse tumor 4T1 showed that administration of this vaccine therapeutically mitigates primary cancer growth as well as distance metastasis. In conclusion, we demonstrate preparation, characterization and pre-clinical application of a novel peptide cancer vaccine.

The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis

“…However, only a minority of patients get durable survival from immunotherapy ( Hegde and Chen, 2020 ). Meanwhile, due to the high cost of immunotherapy ( Yong et al, 2022 ) and immune-related adverse reactions ( Yu et al, 2021 ), it is necessary to standardize the application of ICIs. Appropriate baseline characteristics contribute to implementing rational therapeutic strategies.…”

A systematic review on the molecular and clinical association between Human Papillomavirus and Human Immunodeficiency Virus co‐infection in Head, Neck and Oral squamous cell carcinoma

“…Two phase I/II clinical trials in individuals with squamous cell carcinoma have also used this medication to treat a variety of HPV‐associated malignancies. Individuals with chronic, HPV‐positive OSCC are being treated in phase I/II trials with randomisation to AXAL, durvalumab, or both (NCT02291055) 119,120 …”

High-performance miniature linear time-of-flight mass spectrometry as an advantageous tool in a high mass-to-charge range

“…The spectrum can further be used to calculate the hapten density (weighted average number of molecules linked to each protein) of protein conjugates accurately. 48 The miniature instrument's superior performances are very significant when compared with the commercial full-sized instru- ment. As can be seen from the result, the spectrum (top, Fig.…”